Australia markets open in 5 hours 52 minutes

    +32.10 (+0.48%)

    -0.0030 (-0.41%)
  • ASX 200

    +22.40 (+0.34%)
  • OIL

    +0.54 (+1.27%)
  • GOLD

    -37.30 (-1.99%)

    -32.85 (-0.13%)
  • CMC Crypto 200

    +0.90 (+0.25%)

H2 2020 Osteogenesis Imperfecta Pipeline Review -

·4-min read

The "Osteogenesis Imperfecta - Pipeline Review, H2 2020" drug pipelines has been added to's offering.

This report provides an overview of the Osteogenesis Imperfecta (Genetic Disorders) pipeline landscape.

Osteogenesis imperfecta (OI) is a genetic disorder characterized by bones that break easily, often from little or no apparent cause. This disease is caused by a defect, or flaw, in the gene that produces type 1 collagen, a protein used to create bone. Symptoms include bone deformities, multiple broken bones, loose joints, weak teeth, heart defects and respiratory problems. Treatment includes bisphosphonates and surgery.

The report provides comprehensive information on the therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also reviews the key players involved in therapeutic development for Osteogenesis Imperfecta and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 4 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteogenesis Imperfecta (Genetic Disorders).

  • The pipeline guide reviews pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Osteogenesis Imperfecta (Genetic Disorders) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Osteogenesis Imperfecta (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteogenesis Imperfecta (Genetic Disorders)

Reasons to Buy

  1. Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  2. Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  3. Find and recognize significant and varied types of therapeutics under development for Osteogenesis Imperfecta (Genetic Disorders).

  4. Classify potential new clients or partners in the target demographic.

  5. Develop tactical initiatives by understanding the focus areas of leading companies.

  6. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  7. Formulate corrective measures for pipeline projects by understanding Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

  8. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  9. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:


Report Coverage

  • Osteogenesis Imperfecta - Overview

  • Osteogenesis Imperfecta - Therapeutics Development

Pipeline Overview

  • Pipeline by Companies

  • Products under Development by Companies

Osteogenesis Imperfecta - Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Osteogenesis Imperfecta - Companies Involved in Therapeutics Development

  • Amgen Inc

  • Aptacure Therapeutics Ltd

  • Bone Therapeutics SA

  • Genzyme Corp

  • Keros Therapeutics Inc

  • Mereo Biopharma Group Plc

  • Mesentech Inc

Osteogenesis Imperfecta - Drug Profiles

  • ALLOB - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

  • Aptamer to Inhibit Sclerostin for Osteogenesis Imperfecta - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

  • denosumab - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

  • fresolimumab - Drug Profile

  • Product Description

  • Mechanism Of Action

  • R&D Progress

Osteogenesis Imperfecta - Dormant Projects

  • Osteogenesis Imperfecta - Discontinued Products

  • Osteogenesis Imperfecta - Product Development Milestones

Featured News & Press Releases


  • Methodology

  • Coverage

  • Secondary Research

  • Primary Research

  • Expert Panel Validation

  • Contact

  • Disclaimer

For more information about this drug pipelines report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900